MicroSigX is a biotech diagnostic company founded by world-renowned clinician-scientists committed to developing the world's first microbiome-based diagnostic technologies. With a clear purpose to transform lives through microbial diagnostics, MicroSigX is pioneering proprietary stool-based technologies that decode microbiome signatures to deliver rapid, accurate, and cost-effective non-invasive diagnostic solutions. MicroSigX portfolio focuses on three major global health challenges: colorectal cancer (CRC), inflammatory bowel disease (IBD), and autism spectrum disorder (ASD). Backed by strong clinical validation and a multidisciplinary team, MicroSigX integrates scientific excellence with commercial scalability, aiming to eliminate diagnostic uncertainty and position Hong Kong as a global leader in the microbiome diagnostics industry.